ASX Announcements

2RT Presentation Professor Robyn H Guymer Today 15 Sept 2022

ASX Announcement General AlphaRET

15 Sept, 2022

AGM Date and Directors Nominations

ASX Announcement General iTrack Molteno3 AlphaRET

14 Sept, 2022

EYE 2RT Webinar Prof Guymer

ASX Announcement General iTrack Molteno3 AlphaRET

9 Sept, 2022

EYE FY22 Appendix 4G & Governance Statement

ASX Announcement General iTrack Molteno3 AlphaRET

26 Aug, 2022

EYE FY22 Results Presentation

ASX Announcement General iTrack Molteno3 AlphaRET

26 Aug, 2022

EYE FY22 Results Announcement

ASX Announcement General iTrack Molteno3 AlphaRET

26 Aug, 2022

EYE FY22 Appendix 4E & Annual Report

ASX Announcement General iTrack Molteno3 AlphaRET

26 Aug, 2022

Sales Performance Glaucoma Surgical Devices Segment

ASX Announcement General iTrack Molteno3

8 July, 2022

Nova Eye Medical Launches iTrack Advance

ASX Announcement General iTrack Molteno3 AlphaRET

8 June, 2022

2RT Pivotal Study and Regulatory Pathway Presentation

ASX Announcement General AlphaRET

3 May, 2022

Nova Eye Medical Announces Regulatory Pathway for AlphaRET 2RT in the USA

ASX Announcement General AlphaRET

3 May, 2022

EYE Appointment to AGS Board

ASX Announcement iTrack

31 Mar, 2022

Investor Presentation Half Year Results 31 December 2021

ASX Announcement General iTrack Molteno3 AlphaRET

17 Feb, 2022

Global Revenue of A$6.5m for 6 Months Ended 31 Dec 2021

ASX Announcement General iTrack Molteno3 AlphaRET

17 Feb, 2022

Half Yearly Report and Accounts

ASX Announcement General iTrack Molteno3 AlphaRET

17 Feb, 2022

Glaucoma Sales Update for 6 Months Ended 31 Dec 2021

ASX Announcement General iTrack

1 Feb, 2022

Presentation - Reducing Progression Rate of Age-Related Macular Degeneration

ASX Announcement General AlphaRET

21 Dec, 2021

Appendix 3Z Final Director's Interest Notice

ASX Announcement General

25 Nov, 2021

2021 Annual General Meeting Voting Results

ASX Announcement General

25 Nov, 2021

Presentation - Annual General Meeting 2021

ASX Announcement General

24 Nov, 2021

Withdrawal of AGM Resolutions 2,4,6,7,8 and 9 From Notice of Meeting

ASX Announcement General

24 Nov, 2021

Resignation of Mr Alex Sundich

ASX Announcement General

24 Nov, 2021

Jobkeeper Payments Notification

ASX Announcement General

11 Nov, 2021

US Government Stimulus Loan Forgiven

ASX Announcement General

26 Oct, 2021

Notice of Annual General Meeting

ASX Announcement General

21 Oct, 2021

5-Year Efficacy and Safety of iTrack™ to be Spotlighted at ESCRS 2021

ASX Announcement General iTrack Molteno3 AlphaRET

7 Oct, 2021

EYE FY21 Date of AGM & Closing Date for Director Nominations

ASX Announcement General iTrack Molteno3 AlphaRET

30 Sept, 2021

Nova Eye Medical to Present at ASX Small to Mid-Cap Conference

ASX Announcement General iTrack Molteno3 AlphaRET

10 Sept, 2021

Nova Eye Medical Acquires Key Glaucoma Patents to Drive New Product Expansion

ASX Announcement General iTrack

26 Aug, 2021

Nova Eye Medical Reports 25% Growth in Glaucoma Device Sales for the 2021 Fiscal Year

ASX Announcement General

19 Aug, 2021

Appendix 4E

ASX Announcement General

19 Aug, 2021

Appendix 4G & Corporate Governance Statement

ASX Announcement General

19 Aug, 2021

Notice of Upcoming Investor Call – Full Year (FY21) Results

ASX Announcement General

11 Aug, 2021

Notice of change of interests of substantial holder

ASX Announcement General

29 July, 2021

Nova Eye Medical FY21 Trading Update

ASX Announcement General

20 July, 2021

Nova Eye Establishes Share Sale Facility for Unmarketable Parcels

ASX Announcement General

15 July, 2021

Nova Eye Medical Files IDE Application with the FDA to Commence a Pivotal Study in the US Evaluating 2RT

ASX Announcement AlphaRET

5 July, 2021

2RT® Featured at the 2021 Meeting of the Association for Research in Vision and Ophthalmology

ASX Announcement General AlphaRET

3 May, 2021

Notice of Change of Interests of Substantial Holder

ASX Announcement General

30 Apr, 2021

First Patient Enrolled in MAGIC Clinical Trial for Glaucoma

ASX Announcement General iTrack

30 Apr, 2021

Five-Year Post-LEAD Review Shows Improvement in 2RT® Treatment Benefits for iAMD

ASX Announcement General AlphaRET

5 Mar, 2021

Clinical Trial to Assess Efficacy and Safety of iTrack™ in the Treatment of Mild to Moderate Glaucoma

ASX Announcement General iTrack

2 Mar, 2021

First Half FY2021 Accounts

ASX Announcement General

25 Feb, 2021

1HFY21: Growth in Glaucoma Surgical Devices Segment Despite Pandemic

ASX Announcement General

25 Feb, 2021

Notice of Upcoming Investor Call – First Half FY21 Results

ASX Announcement General

18 Feb, 2021

Notice of Change of Interests of Substantial holder

ASX Announcement General

14 Dec, 2020

Appendix 2A

ASX Announcement General

9 Dec, 2020

Poll Results Annual General Meeting 2020

ASX Announcement General

27 Nov, 2020

Chairman’s Address to Annual General Meeting

ASX Announcement General

27 Nov, 2020

PRESENTATION AND UPDATE, ANNUAL GENERAL MEETING 2020

ASX Announcement General

27 Nov, 2020

Strong Rebound for Glaucoma Surgical Device Sales in FY21

ASX Announcement General

25 Nov, 2020

2RT® Clinical Update: Sub-Study Analysis of LEAD Trial Demonstrates Improved Retinal Function Following Treatment with 2RT®

ASX Announcement General

16 Nov, 2020

Notice of Annual General Meeting

ASX Announcement General

26 Oct, 2020

Nova Eye Medical Establishes AlphaRET to Support Commercial Development of 2RT®

ASX Announcement AlphaRET

26 Oct, 2020

Date of AGM and Closing Date for Director Nominations

ASX Announcement General

8 Oct, 2020

For investor enquires please contact:

Mark Flynn
Nova Eye Medical Limited
W +61 416 068 733
mflynn@nova-eye.com

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More